ReviewClinical ophthalmology (Auckland, N.Z.)2026
Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis.
Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Low-dose atropine has been increasingly investigated as a pharmacological intervention to slow myopia progression in children. However, variability in atropine concentrations and reported outcomes across randomised clinical trials has led to uncertainty regrading its overall efficacy and safety. This systematic review and meta-analysis evaluated the efficacy and safety of low-dose atropine eye drops (0.01-0.05%) in slowing myopia progression in children. Patients and Methods: This review followed PRISMA guidelines and was registered in PROSPERO (CRD42025635523). A comprehensive search of PubMed, ScienceDirect, MedLine, and the Cochrane Library was conducted in January 2025. Eligible studies were randomized controlled trials from 2019 to 2024 involving children aged 4-18 years with progressive myopia. Low-dose atropine concentrations evaluated across studies included 0.01%, 0.02%, 0.025%, and 0.05%, compared with placebo or control interventions. Data extraction and risk of bias assessment using the Cochrane Risk of Bias 2.0 tool were performed independently by multiple reviewers. Meta-analysis was conducted using Review Manager (RevMan) 5.4 on Mean changes in axial length and spherical equivalent. Fixed or random effects models were applied based on heterogeneity (I Results: Thirteen randomized controlled trials involving 2529 children were included. Low-dose atropine (0.01-0.05%) significantly reduced axial elongation compared with placebo (mean difference [MD]: -0.11 mm; 95% CI: -0.13 to -0.09; p < 0.00001) with substantial heterogeneity (I Conclusion: Low-dose atropine (0.01-0.05%) may be an effective and generally safe intervention for slowing myopia progression in children. While the findings support its potential role in myopia control, further long-term trials are needed to clarify optimal dosing strategies and sustained post-treatment effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.